| 产品描述: | KH-CB19 is a potent CLK (cdc2-like kinase) inhibitor (CLK1 IC50=19.7 nM; CLK3 IC50=530 nM). KH-CB19 shows antiviral activity and inhibits influenza virus replication (IC50=13.6 μM) |
| 靶点: |
CLK1:19.7 nM (IC50);CLK3:530 nM (IC50);DYRK1A:55.2 nM (IC50);Others |
| 体外研究: |
KH-CB19 (10 μM; 1 h) shows CLK inhibition on SR protein phosphorylation in human microvascular endothelial cells. KH-CB19 (50 μM; 6 h) inhibits the disruption by CLK4 in A549 cells. Western Blot Analysis Cell Line: Human microvascular endothelial cells (HMEC-1) Concentration: 10 μM Incubation Time: 1 hour Result: Led to a reduced phosphorylation of SRp75, SRp55, and SRp20 compared with non TNF-α-stimulated controls.Led to a reduction of the TNF-α-induced increase in phosphorylation of all analyzed SR proteins compared with TNF-α-stimulated controls. |
| 参考文献: |
1. Fedorov O, et al. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol. 2011 Jan 28;18(1):67-76. 2. Artarini A, et al. Regulation of influenza A virus mRNA splicing by CLK1. Antiviral Res. 2019 Aug;168:187-196. |
| 溶解性: |
soluble in DMSO |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.957 ml |
14.785 ml |
29.569 ml |
| 5 mM |
0.591 ml |
2.957 ml |
5.914 ml |
| 10 mM |
0.296 ml |
1.478 ml |
2.957 ml |
| 50 mM |
0.059 ml |
0.296 ml |
0.591 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |